190 related articles for article (PubMed ID: 7914470)
21. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
22. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
24. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
25. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
[TBL] [Abstract][Full Text] [Related]
28. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
Choy H; Akerley W; Safran H; Clark J; Rege V; Papa A; Glantz M; Puthawala Y; Soderberg C; Leone L
J Clin Oncol; 1994 Dec; 12(12):2682-6. PubMed ID: 7989944
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
31. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
32. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR
J Clin Oncol; 1996 Jan; 14(1):142-8. PubMed ID: 8558189
[TBL] [Abstract][Full Text] [Related]
35. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
36. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
DeVore RF; Jagasia M; Johnson DH
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
[TBL] [Abstract][Full Text] [Related]
38. [Phase I study of paclitaxel].
Horikoshi N; Inoue K; Aiba K; Mukaiyama T; Ogihara A; Sumida T; Akatsuka Y; Besho A; Inamoto Y; Uchida T
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2407-14. PubMed ID: 7944484
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
Chang AY; Boros L; Garrow G; Asbury R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):124-7. PubMed ID: 7597429
[TBL] [Abstract][Full Text] [Related]
40. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
